Melinta Therapeutics, Inc.  

(Public, NASDAQ:MLNT)   Watch this stock  
Find more results for NASDAQ:CEMP
16.10
+0.90 (5.92%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.14 - 16.15
52 week 10.25 - 37.00
Open 15.20
Vol / Avg. 380,690.00/160,787.00
Mkt cap 169.09M
P/E     -
Div/yield     -
EPS -7.34
Shares 10.50M
Beta 1.16
Inst. own 59%
Nov 29, 2017
Melinta Therapeutics, Inc. to Acquire Infectious Disease Business from Medicines Co Conference Call - Webcast
Nov 3, 2017
Cempra Inc Annual Shareholders Meeting
Nov 2, 2017
Q3 2017 Cempra Inc Earnings Release (Estimated)
Sep 26, 2017
Cempra Inc at Ladenburg Thalmann Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -603.32% -654.76%
Operating margin -613.45% -650.58%
EBITD margin - -650.29%
Return on average assets -22.43% -58.88%
Return on average equity -28.08% -78.38%
Employees 45 -
CDP Score - -

Address

300 George St Ste 301
NEW HAVEN, CT 06511-6663
United States - Map
+1-312-7670291 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company also has an extensive pipeline of preclinical and clinical stage products This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market.

Officers and directors

Kevin T. Ferro Chairman of the Board
Age: 45
Bio & Compensation  - Reuters
Daniel M. Wechsler President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Paul Estrem Chief Financial Officer
Bio & Compensation  - Reuters
John D. Bluth Executive Vice President - Investor Relations and Corporate Communications
Age: 44
Bio & Compensation  - Reuters
Lyn Baranowski Senior Vice President - Corporate Development and Strategy
Bio & Compensation  - Reuters
Peter DiRoma Senior Vice President - Regulatory Affairs and Quality Assurance
Bio & Compensation  - Reuters
Erin M. Duffy Ph.D. Chief Scientific Officer
Age: 45
Bio & Compensation  - Reuters
Suzie Paulson Vice President of Human Resources
Bio & Compensation  - Reuters
Kevin Conway Vice President - Program Management and Technical Operations
Bio & Compensation  - Reuters
Sue Cammarata M.D. Chief Medical Officer
Bio & Compensation  - Reuters